The following is a summary of “Retrospective evaluation of novel serum inflammatory biomarkers in first-episode psychiatric disorders: diagnostic potential and immune dysregulation,” published in the December 2024 issue of Psychiatry by Qiu et al.
Researchers conducted a retrospective study to evaluate the diagnostic capabilities of eight inflammatory biomarkers in first-episode schizophrenia, bipolar disorder (BD), and depression (D). The study examined the differential expression of markers including neutrophils/lymphocyte ratio (NLR), aggregate index of systemic inflammation (AISI), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), lymphocytes/high-density lipoprotein (HDL) ratio (LHR), monocytes/HDL ratio (MHR), neutrophils/HDL ratio (NHR), and platelets/HDL ratio (PHR) across these conditions.
They conducted a retrospective observational study with 335 individuals diagnosed with schizophrenia (SCZ), 68 with BD, 202 with D, and 282 healthy controls (C). Hematologic parameters were evaluated from untreated patients and controls.
The results showed significant differences in biomarker levels between patient groups and controls. Logistic regression identified NHR and MHR (P < 0.001), LHR and NLR (P < 0.01) as predictive for SCZ. MHR was predictive for BD (P < 0.05). NHR (P < 0.01) and MHR (P < 0.001) distinguished D from C. The AUC for the SCZ model (NHR + MHR + NLR) was 0.846 (P < 0.001), for BD (MHR) 0.816 (P < 0.001), and for D (NHR + MHR) 0.824 (P < 0.001).
Investigators highlighted the diagnostic value of inflammatory biomarkers in distinguishing schizophrenia, BD, and D.
Source: frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1442954/full
